Next 10 |
home / stock / amrn / amrn articles
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a confere...
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial result...
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter fin...
Amarin Corporation Plc (NASDAQ:AMRN) reported fourth-quarter 2023 revenues of $74.71 million, down from $90.2 million, beating the consen...
Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company announced a strategic combination with Inf...
U.S. stocks traded lower, with the Dow Jones index falling over 150 points on Thursday. Shares of Aspen Aerogels, Inc. (NYSE: ASPN) fell sharply du...
Amarin Corp PLC (NASDAQ: AMRN) shares are trading by around 28% after the company reported preliminary Q4 FY23 results. AMRN expects reve...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Wednesday. The Dow traded up 0.29% to 37,6...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
2024-07-31 14:15:16 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q2 2024 Earnings Call Jul 31, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
Dayforce Inc. (DAY) is expected to report $0.18 for Q2 2024 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.44 for Q2 2024 Aurora Innovation Inc. (AUR) is expected to report for Q2 2024 Autohome Inc. American Depositary Shares each repr...
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...